Nervous Disorder TRIZ Cases

Engineered mutant EGF polypeptides increase binding affinity to EGFR by up to 100-fold, resolving insufficient potency in existing therapies.

A Lactobacillus reuteri ATG-F4 strain enhances dopamine secretion through microbial metabolic activity in the gut.

A decoy peptide neutralizes plasma IgG autoantibodies targeting the serotonin 2A receptor to block harmful signaling pathways.

Modified oligonucleotides block VLA-4 integrin mRNA translation, reducing new active brain lesions and disease progression while minimizing side effects.

A transdermal therapeutic system combines oxybutynin with rivastigmine to deliver higher acetylcholinesterase inhibitor doses.

BTLA agonist fusion proteins bind the BTLA receptor to enhance signaling, resolving the failure of antibody therapies in human clinical applications.

Ethyl acetate fractions from centipede grass reduce BACE1 enzyme activity, addressing hypoglycemia risks associated with synthetic anti-diabetic drugs.

A live attenuated Bordetella pertussis vaccine induces protective immune responses to reduce beta-amyloid plaque formation in the brain.

Rigid cyclopropane analogues improve plasma half-life and neurological bioavailability by activating mitofusin.

Oral Lactobacillus fermentum PS150 reduces stress hormones and inflammatory cytokines to treat anxiety and depression.

Modified alpha-neurotoxin polypeptides inhibit protein kinases, resolving the lack of effective inhibition mechanisms in current treatments.

HDAC inhibitors upregulate DJ-1 to counteract oxidative stress and protein aggregation in neurodegenerative disease models.

Compounds of formula I to IV bind E3 ligases non-covalently.

A herbal pharmaceutical composition manages withdrawal symptoms and reduces relapse rates.

Ibudilast treats alcohol use disorder with comorbid depression by reducing craving while avoiding side effects of conventional agents.

A three-enzyme biosynthetic pathway in yeast or bacteria converts p-coumaric acid to pterostilbene, resolving low industrial production efficiency.

Soluble CR2 proteins with amino acid substitutions deliver complement modulators to specific sites.

Segmented synthesis of cyclic depsipeptides improves HDAC inhibitor preparation efficiency and specificity.

Oxytocin mediates respiratory recovery via non-opioid pathways, preserving analgesia while reversing depression.

Combines baclofen, sorbitol, and naltrexone to promote nerve regeneration.

Eight novel crystalline forms of morphine sulfate enable sustained-release pharmaceutical compositions with improved stability.

D-amino acid oxidase inhibitors address inadequate efficacy data for ataxic disorders by boosting endogenous D-serine to ameliorate neurodegenerative symptoms.

Isolated diterpene glycosides deliver effective pain relief without capsaicin-induced burning sensations or erythema.

Fluorinated conotoxin peptide analogs constrain the alpha9alpha10 nicotinic acetylcholine receptor to deliver targeted analgesia.

Recrystallizing J147 into Form II resolves stability and solubility bottlenecks, enabling effective pharmaceutical administration.

Purified cannabidiol addresses treatment-resistant epilepsy by reducing seizure frequency in BRAF mutation patients.

Intravenous liposomal curcumin crosses the blood-brain barrier, preventing neuronal damage and stimulating neurogenesis for neurodegenerative disorders.

A cholinergic composition treats autonomic dysfunction using synergistic agents.

GLYX-13 peptide modulates the glycine site of the NMDA receptor to treat depression without dissociative side effects.

Spirolactone compounds inhibit ACC1 and ACC2 enzymes, reducing malonyl-CoA production to treat non-alcoholic steatohepatitis.

A topical cream composition reduces muscular pain using natural oils and butters.

Local injection of botulinum toxin into facial muscles inhibits acetylcholine release, reducing stress symptoms without systemic side effects.

A dietary supplement composition combining NADH, Coenzyme Q10, Vitamin C, and serine to promote natural adrenaline production.

Antisense oligonucleotides induce exon skipping in SORL1 pre-mRNA transcripts to restore functional protein production.

Novel verubecestat crystalline forms improve stability and bioavailability to reduce amyloid beta production in Alzheimer's disease treatment.

Modified AC253 sequences achieve blood-brain barrier penetration and proteolytic stability, reversing cognitive deficits in Alzheimer's models.

Co-administering metformin, antioxidants, and lipid stabilizers mitigates cerebral ischemia damage while improving post-arrest survival rates.

CRISPR/Cas3 editing inserts a suicide gene into neural stem cells, resolving the contradiction between therapeutic efficacy and tumorigenicity risks.

A mannitol-based topical composition delivers transdermal pain relief through osmotic and antioxidant mechanisms.

BAFFR antagonist antibodies deplete B cells to treat autoimmune diseases without broad immunosuppression side effects.

Humanized antibodies bind human IL-23p19 to suppress inflammation while reducing immunogenicity risks from rodent-derived sequences.

Merging a dopamine receptor agonist with a monoamine oxidase inhibitor in specific molar ratios restores locomotion activity while attenuating neuronal damage.

Segmenting the dosage form resolves solubility mismatches between acetaminophen and tramadol, achieving synchronized plasma concentrations.

Fully human antibodies bind the CCR2 receptor with high affinity to inhibit chemokine interactions.

Positioning a deep brain stimulation electrode in the dorsal-lateral and anterior subthalamic nucleus region to modulate neural activity.

Antibodies detect S38AA polypeptide fragments in cerebrospinal fluid to resolve diagnostic reliability and sensitivity trade-offs.

Stabilized YEVHHQ peptide derivatives neutralize toxic beta-amyloid oligomers, addressing the limitation of transient symptom relief in Alzheimer's treatments.

Recombinant T cell receptor ligands link MHC domains to neural antigens to reverse persistent cognitive impairments in substance addiction.